Stay updated with breaking news from Complete Remission. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) unveiled promising results from its BEXMAB trial at a leading medical conference, showcasing a new...
Actinium Pharmaceuticals, Inc. reported results from the Phase 3 SIERRA trial of Iomab-B. The company said Iomab-B achieved the primary endpoint in the SIERRA trial of durable Complete Remission or dCR of at least 6 months with high statistical significance, with 22% of patients randomized to the Iomab-B arm achieving dCR and 0% of patients in the control arm achieving dCR, irrespective of TP53 mutational status.
Experts recently debated whether additional intensive therapy can improve posttransplant outcomes for patients with acute myeloid leukemia who have residual disease after induction therapy.
/PRNewswire/ -- Guangzhou Gloria Biosciences ("GloriaBio"), a commercial stage biopharmaceutical company focusing on the discovery, development and...
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...